ReviewClinical kidney journal2026
Ten tips for ordering, interpreting, and communicating genetic test results in nephrology.
Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic testing is becoming a routine-and increasingly time-sensitive-tool in nephrology, with implications for diagnosis, prognosis, targeted therapy, transplant planning, and family counselling. However, many nephrologists remain uncomfortable with genetic concepts in general, and variant interpretation specifically. This gap will increasingly limit their ability to fully leverage genetic testing in routine nephrology care-and to translate results into management decisions that improve patient outcomes. In this review, we provide 10 practical tips to help nephrologists integrate genetic testing safely and confidently into everyday practice. We emphasize early testing when a molecular diagnosis could plausibly change management, and the primacy of careful phenotyping (including extra-renal features) to guide efficient test selection (single-gene testing, targeted panels, exome, or genome). We outline a pragmatic approach to informed consent that addresses the family impact, secondary findings, and the possibility of misattributed parentage. We then walk through how to read genetic reports, recognize common technical 'blind spots' (e.g. copy number variants), and classify results in a clinically meaningful way (diagnostic, suggestive, or uninformative). We highlight how to handle variants of uncertain significance as hypotheses rather than diagnoses, and why periodic reanalysis is essential as gene-disease assertions and variant classifications evolve. Finally, we encourage clinicians to work within multidisciplinary pathways and to contribute to data-sharing efforts that advance nephrogenetics. Each tip concludes with a brief 'nephrogenetics nugget'-a practical takeaway, a useful metaphor, or a simple script-to help clinicians translate core concepts into real-world conversations and decisions at the point of care. Overall, these tips provide a practical framework for ordering, interpreting, and disclosing genetic test results in routine nephrology care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.